Literature DB >> 25549071

Phospholipase A2 group v in benign familial fleck retina in a set of triplets.

Ng Jun Bin1, Hah Moon Heng, Rozaida Poh, Suzita Mohd Noor, Visvaraja Subrayan.   

Abstract

PURPOSE: To evaluate the association of phospholipase A2, Group V (PLA2G5), with benign familial fleck retina in a consanguineous family with triplets.
METHODS: Clinical eye examination, including fundus examination and spectral domain optical coherence tomography, was performed for all the family members. After blood sample collection and DNA extraction, polymerase chain reaction was performed to amplify regions spanning Exons 2, 3, 4, and 5 of PLA2G5. The amplified products were sequenced to observe the presence of any mutations.
RESULTS: Fundus examination in two of the triplets revealed discrete yellow-white flecks and both had good vision and absence of night blindness, consistent with benign familial fleck retina. The flecks were hyperautofluorescent. Furthermore, spectral domain optical coherence tomography showed focal thickening of the retinal pigment epithelium because of the presence of these flecks. Molecular investigations showed that PLA2G5 Exons 2, 4, and 5 harbored no misalignments among all family members. However, PLA2G5 Exon 3 showed a p.Gly45Cys mutation for the father and the third triplet who was affected.
CONCLUSION: The clinical findings in this family suggest a diagnosis of benign familial fleck retina with excellent prognosis, in which the PLA2G5 gene may play a role.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25549071     DOI: 10.1097/IAE.0000000000000446

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  1 in total

1.  Multimodal imaging including optical coherence tomography angiography of benign familial fleck retina.

Authors:  George J Manayath; Shishir Verghese; Hirika Vipul Gosalia; Anuradha Kanakath; Venkatapathy Narendran
Journal:  Oman J Ophthalmol       Date:  2022-03-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.